๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Aripiprazole

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our China and USA registers that name Aripiprazole as an intervention. Synced 24 Sep 2026
5Trials tracked
2Recruiting now
5Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Aripiprazole is named as a drug or biological intervention in 5 clinical trials in our China and USA trial registers, 2 of which are recruiting. Lead sponsors include Minerva Neurosciences (1), Xinyu Zhou (1) and Central South University (1). Registered phases: Phase 3, Phase 4, Not applicable, Phase 2 and Phase 1/2. Conditions studied include Major Depressive Disorder (MDD); Negative Symptoms of Schizophrenia; Rumination.

Aripiprazole also has an approved-drug profile on this site (FDA label data): Abilify (Aripiprazole) →
01

Clinical trials of Aripiprazole

5 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07565428 Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications (ClinicalTrials.gov ↗)
Negative Symptoms of Schizophrenia
Phase 3 Recruiting Minerva Neurosciences USA
NCT05814640 Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (ClinicalTrials.gov ↗)
Depression, Sequestra
Phase 1/2 Recruiting First Affiliated Hospital of Chongqing Medical University China
NCT07011693 Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression๏ผˆSMART-I)
Major Depressive Disorder (MDD)
Phase 4 Not yet open Xinyu Zhou China
NCT07703956 Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults (ClinicalTrials.gov ↗)
Schizophrenia
Phase 2 Not yet open Vigonvita Life Sciences China
NCT06937476 Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (ClinicalTrials.gov ↗)
Major Depressive Disorder (MDD), Rumination
Not applicable Active, closed Central South University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

6 conditions
Condition (as registered)Trials
Major Depressive Disorder (MDD)2
Negative Symptoms of Schizophrenia1
Rumination1
Schizophrenia1
Depression1
Sequestra1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Minerva Neurosciences1
Xinyu Zhou1
Central South University1
Vigonvita Life Sciences1
First Affiliated Hospital of Chongqing Medical University1
04

Trials by country register

RegisterAripiprazole trials
Clinical trials in China4
Clinical trials in USA1

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Aripiprazole works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aripiprazole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.